Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Can-Fite Biopharma Ltd ADR
(NY:
CANF
)
2.020
-0.030 (-1.46%)
Official Closing Price
Updated: 4:10 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Can-Fite Biopharma Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Can-Fite Revenue FY22 Revenue Declines 4.7%, Here Is What You Need To Know
March 30, 2023
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months...
Via
Benzinga
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
March 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
March 16, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
March 13, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
February 14, 2023
During Tuesday, 40 stocks hit new 52-week lows.
Via
Benzinga
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
February 14, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
February 10, 2023
During Friday, 48 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
January 25, 2023
On Wednesday, 22 companies hit new 52-week lows.
Via
Benzinga
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
January 24, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
January 11, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
January 10, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
January 04, 2023
On Wednesday, 35 companies reached new 52-week lows.
Via
Benzinga
Can-Fite Announces ADS Ratio Change
December 30, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer
December 28, 2022
Via
Benzinga
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
December 28, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results
December 27, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results
December 27, 2022
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.
Via
TheNewswire.com
Multiple Shots On Goal: Can-Fite's Late-Stage Clinical Pipeline Hits Positive Results
December 13, 2022
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.
Via
Benzinga
Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
December 08, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
November 25, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Meet This BioPharma Company With Several Exciting Drugs In Advanced Clinical Trials
November 09, 2022
Sign up for this week’s All Access giveaway here! Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma (NYSE: CANF), was a guest on Benzinga’s All Access on Nov 4, 2022.
Via
Benzinga
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
November 02, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
October 31, 2022
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.
Via
TheNewswire.com
Exposures
Product Safety
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
October 27, 2022
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.
Via
Benzinga
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
October 25, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
October 13, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite BioPharma Ltd. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
September 23, 2022
Via
ACCESSWIRE
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
August 25, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology
September 12, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
August 23, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.